中国药物经济学2025，Vol.20Issue(3)：17-23,28,8.DOI:10.12010/j.issn.1673-5846.2025.03.003
维立西呱治疗心力衰竭的快速卫生技术评估
Rapid Health Technology Assessment of Viliciclovir in the Treatment of Heart Failure
廖磊 1杨继莹 2马继敏 1袁明聪 3王重惠 1王学昌4
作者信息
- 1. 昆明医科大学药学院,昆明 650000
- 2. 大理州宾川县疾控中心,云南 大理 671699
- 3. 大理大学药学院,云南 大理 671000
- 4. 昆明理工大学附属安宁市第一人民医院药学部,昆明 650302
- 折叠
摘要
Abstract
Objective To rapidly assess the effectiveness,safety,and cost-effectiveness of vericiguat in the treatment of heart failure(HF),providing evidence-based support for clinical decision-making.Methods Systematic searches of Chinese and international databases,as well as official websites of health technology assessment(HTA)agencies,were conducted to collect research literature on vericiguat for heart failure published before August 2024.Two reviewers screened the literature based on inclusion and exclusion criteria,extracted data,assessed quality,and performed a comprehensive analysis.Results One HTA report,nine systematic reviews/Meta-analyses,and seven pharmacoeconomic studies were included.In terms of effectiveness,vericiguat significantly reduced hospitalization rates in all HF patients compared to placebo,improved the composite outcome of cardiovascular death or HF hospitalization in patients with heart failure with reduced ejection fraction(HFrEF),lowered all-cause mortality and N-terminal pro-B-type natriuretic peptide(NT-proBNP)levels,and offered some benefit in quality of life improvement.However,vericiguat showed no significant clinical benefit for patients with heart failure with preserved ejection fraction(HFpEF)or mid-range ejection fraction(HFmEF).Compared with sacubitril-valsartan,vericiguat showed no significant difference in reducing cardiovascular death and HF hospitalization risk in HFrEF patients,and its efficacy was not inferior.In terms of safety,vericiguat did not significantly differ from placebo in the incidence of adverse reactions leading to discontinuation or serious adverse events.Common side effects included mild hypotension,anemia,and syncope.Economically,long-term use of vericiguat for HFrEF patients in China is not cost-effective,but it shows economic advantage when combined with standard therapy in patients with NT-proBNP≤5314 pg/ml.Conclusion Vericiguat is effective and safe for HFrEF treatment,though it lacks cost-effectiveness in China,except for patients with NT-proBNP≤5314 pg/ml.Its therapeutic value is limited for HFpEF and HFmEF patients.关键词
维立西呱/心力衰竭/快速卫生技术评估/药物经济学Key words
Vericiguat/Heart failure/Rapid health technology assessment/Pharmacoeconomic分类
临床医学引用本文复制引用
廖磊,杨继莹,马继敏,袁明聪,王重惠,王学昌..维立西呱治疗心力衰竭的快速卫生技术评估[J].中国药物经济学,2025,20(3):17-23,28,8.
